Pyxis Oncology (PYXS) Gets a Buy from RBC Capital

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $4.96.

Timashev covers the Healthcare sector, focusing on stocks such as Legend Biotech, Axsome Therapeutics, and NewAmsterdam Pharma Company. According to TipRanks, Timashev has an average return of 22.5% and a 42.86% success rate on recommended stocks.

Currently, the analyst consensus on Pyxis Oncology is a Strong Buy with an average price target of $7.33, implying a 47.78% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.

Based on Pyxis Oncology’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $600 thousand and a GAAP net loss of $23.05 million. In comparison, last year the company had a GAAP net loss of $27.67 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pyxis Oncology (PYXS) Company Description:

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.